CLINICAL_TRIALS
withdrawal
· 2009-11-13
Clinical Trial Update: Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension [Phase 3]
Summary
A Phase 3 study evaluating the addition of sildenafil to bosentan therapy for pulmonary arterial hypertension has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University Health Network, Toronto | Conditions: Hypertension, Pulmonary | Phase 3 | Status: WITHDRAWN